Hepatitis B virus-related hepatocellular carcinoma has superior overall survival compared with other etiologies

被引:1
|
作者
Yen, Yi-Hao [1 ,2 ]
Kee, Kwong-Ming [1 ,2 ]
Hu, Tsung-Hui [1 ,2 ]
Tsai, Ming-Chao [1 ,2 ]
Kuo, Yuan-Hung [1 ,2 ]
Li, Wei-Feng [3 ,4 ]
Liu, Yueh-Wei [3 ,4 ]
Wang, Chih-Chi [3 ,4 ]
Lin, Chih-Yun [5 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan
[3] Kaohsiung Chang Gung Mem Hosp, Liver Transplantat Ctr, Kaohsiung, Taiwan
[4] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Kaohsiung, Taiwan
[5] Kaohsiung Chang Gung Mem Hosp, Biostat Ctr, Kaohsiung, Taiwan
来源
PLOS ONE | 2024年 / 19卷 / 03期
关键词
FATTY LIVER-DISEASE; ASSOCIATION; HCC; RECURRENCE; THERAPY; ALCOHOL;
D O I
10.1371/journal.pone.0290523
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Whether the etiology of chronic liver disease (CLD) impacts the overall survival (OS) of patients with hepatocellular carcinoma (HCC) remains unclear. We aim to clarify this issue. Materials and methods Between 2011 and 2020, 3941 patients who were newly diagnosed with HCC at our institution were enrolled in this study. In patients with multiple CLD etiologies, etiology was classified using the following hierarchy: hepatitis C virus (HCV) > hepatitis B virus (HBV) > alcohol-related > all negative. All negative was defined as negative for HCV, HBV, and alcohol use disorder. Results Among 3941 patients, 1407 patients were classified with HCV-related HCC, 1677 patients had HBV-related HCC, 145 patients had alcohol-related HCC, and 712 patients had all-negative HCC. Using the all-negative group as the reference group, multivariate analysis showed that HBV is an independent predictor of mortality (hazard ratio: 0.856; 95% confidence interval: 0.745-0.983; p = 0.027). Patients with HBV-related HCC had superior OS compared with patients with other CLD etiologies (p<0.001). Subgroup analyses were performed, for Barcelona Clinic Liver Cancer (BCLC) stages 0-A (p<0.001); serum alpha-fetoprotein (AFP) levels >= 20 ng/ml (p<0.001); AFP levels < 20 ng/ml (p<0.001); age > 65 years (p<0.001); and the use of curative treatments (p = 0.002). No significant difference in OS between HBV and other etiologies was observed among patients aged <= 65 years (p = 0.304); with BCLC stages B-D (p = 0.973); or who underwent non-curative treatments (p = 0.1). Conclusion Patients with HBV-related HCC had superior OS than patients with other HCC etiologies.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Comparison of clinical features and survival in patients with hepatitis B and C virus-related hepatocellular carcinoma
    Tanizaki, H
    Ryu, M
    Kinoshita, T
    Kawano, N
    Konishi, M
    Cho, A
    Nakatsura, T
    Natsume, T
    Takahashi, S
    Sugita, M
    Izuishi, K
    Yoshino, M
    Furuse, J
    Iwasaki, M
    Tsubono, Y
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (02) : 67 - 70
  • [22] Impact of Nucleoside Analog Entecavir on Survival of Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma
    Komorizono, Yasuji
    Sako, Katsumi
    Nakaya, Mari
    Shibatou, Toshihiko
    GASTROENTEROLOGY, 2012, 142 (05) : S916 - S916
  • [23] Tenofovir is superior to entecavir on recurrence in hepatitis B virus-related hepatocellular carcinoma after curative resection
    Tsai, Ming-Chao
    Wang, Chih-Chi
    Lee, Wei-Chen
    Liu, Yueh-Wei
    Lin, Chih-Che
    Hu, Tsung-Hui
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 163 - 163
  • [24] Expression of Growth Hormone Receptor Is Associated to Prognosis and Overall Survival in Hepatitis C Virus-related Hepatocellular Carcinoma
    Dai, Chia-Yen
    Lin, Ching-Chih
    Huang, Chung-Feng
    Yeh, Ming-Lun
    Huang, Jee-Fu
    Yu, Ming-Lung
    Chuang, Wan-Long
    HEPATOLOGY, 2017, 66 : 527A - 527A
  • [25] The preoperative positivity for serum hepatitis B e antigen did not affect overall survival after curative resection of hepatitis B virus-related hepatocellular carcinoma
    Choi, Gi Hong
    Kim, Dong Hyun
    Choi, Sae Byeol
    Kang, Chang Moo
    Kim, Kyung Sik
    Choi, Jin Sub
    Lee, Woo Jung
    Han, Kwang Hyub
    Chon, Chae Yoon
    Kim, Byong Ro
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (03) : 391 - 398
  • [26] Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma
    Kubo, Shoji
    Takemura, Shigekazu
    Tanaka, Shogo
    Shinkawa, Hiroji
    Nishioka, Takayoshi
    Nozawa, Akinori
    Kinoshita, Masahiko
    Hamano, Genya
    Ito, Tokuji
    Urata, Yorihisa
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (27) : 8249 - 8255
  • [27] Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma
    Shoji Kubo
    Shigekazu Takemura
    Shogo Tanaka
    Hiroji Shinkawa
    Takayoshi Nishioka
    Akinori Nozawa
    Masahiko Kinoshita
    Genya Hamano
    Tokuji Ito
    Yorihisa Urata
    World Journal of Gastroenterology, 2015, (27) : 8249 - 8255
  • [28] Antiviral Therapy and Hepatitis B Virus-Related Hepatocellular Carcinoma Recurrence
    Hsu, Ching-Sheng
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (08): : 765 - 765
  • [29] Long noncoding RNAs in hepatitis B virus-related hepatocellular carcinoma
    Ting-Ting Yu
    Xi-Ming Xu
    Yi Hu
    Jun-Jian Deng
    Wei Ge
    Na-Na Han
    Mei-Xia Zhang
    World Journal of Gastroenterology, 2015, (23) : 7208 - 7217
  • [30] Role of superoxide dismutase in hepatitis B virus-related hepatocellular carcinoma
    Zhang, Xiaolian
    Lu, Yu
    Rong, Chengzhi
    Yang, Dongmei
    Li, Shan
    Qin, Xue
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2016, 21